



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

February 20, 2020

Via E-mail

Mr. David F. Carroll  
Senior Vice President and Chief Financial Officer  
IVERIC bio, Inc.  
One Penn Plaza, 35th Floor  
New York, NY 10119

**Re: IVERIC bio, Inc.**  
**Form 10-Q for the quarterly period ended September 30, 2019**  
**Exhibit No. 10.1 Exclusive License Agreement**  
**Filed November 12, 2019**  
**File No. 001-36080**

Dear Mr. Carroll:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance